Mirae Asset Global Investments Co., Ltd. Immunovant, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $34.4 Billion
- Q4 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Immunovant, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 8,517 shares of IMVT stock, worth $234,302. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,517
Previous 6,739
26.38%
Holding current value
$234,302
Previous $185,000
26.49%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding IMVT
# of Institutions
215Shares Held
82MCall Options Held
557KPut Options Held
704K-
Deep Track Capital, LP Greenwich, CT9.73MShares$268 Million8.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.78MShares$214 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.84MShares$161 Million2.47% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.22% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.16MShares$142 Million0.05% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...